Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in Relapsed/Refractory Malignant Mesothelioma
NCT02860286Phase 2Completed
- Sponsor
- Epizyme, Inc.
- Start
- Jul 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of tazemetostat in malignant mesothelioma, sponsored by Epizyme, Inc.. Started Jul 2016; status: completed.
02
Drugs
tazemetostat
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT02860286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860286.